# Denosumab for Type 1 Diabetes

> **NCT06524960** · PHASE1,PHASE2 · RECRUITING · sponsor: **City of Hope Medical Center** · enrollment: 45 (estimated)

## Conditions studied

- Type 1 Diabetes

## Interventions

- **DRUG:** Denosumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06524960
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-03
- **Primary completion:** 2027-10-11
- **Final completion:** 2027-10-11
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2025-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06524960

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06524960, "Denosumab for Type 1 Diabetes". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06524960. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*